Stock 0IE3 MOLMED S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights MolMed S.p.A. CBOE EUROPE EQUITIES

Equities

0IE3

IT0001080248

End-of-day quote CBOE EUROPE EQUITIES
Other stock markets
- EUR - Intraday chart for MolMed S.p.A.
2023 Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement CI
2022 AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement
CI
AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies
CI
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
CI
AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility
CI
AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €220 million.
CI
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
CI
AGC Inc. entered into an agreement to acquire MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €240 million.
CI
Molmed S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
Molmed S.P.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
Molmed S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2019
CI
Molmed S.P.A. Reports Earnings Results for Third Quarter and Nine Months Ended September 30, 2018
CI
MolMed S.p.A. and AbCheck s.r.o. Sign A Three-Year Master Agreement for the Development of New Cars Targeting Novel Tumor Antigens
CI
MolMed S.p.A. Announces Earnings Results for the First Quarter Ended March 31, 2018
CI
MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2017
CI
Molmed S.P.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
CI
MolMed S.p.A. Announces Earnings Results for the Six Months Ended June 30, 2017
CI
MolMed S.p.A. and TTY Biopharm Company Ltd Announce Exclusive License and Distribution Agreement
CI
MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2017
CI
Megapharm Enters into Distribution and Licensing Agreement with MolMed for Zalmoxis
CI
MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2016
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MLM Stock
  4. 0IE3 Stock
  5. News MolMed S.p.A.
  6. Highlights